Dynavax Technologies (NASDAQ:DVAX) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

A number of other equities analysts have also commented on DVAX. Cowen reiterated an “outperform” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a report on Thursday, August 10th. ValuEngine lowered shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Royal Bank Of Canada reiterated an “outperform” rating and issued a $28.00 price objective (up previously from $26.00) on shares of Dynavax Technologies in a report on Monday, September 25th. William Blair reissued an “outperform” rating and issued a $30.00 target price on shares of Dynavax Technologies in a research report on Wednesday, August 9th. Finally, Cantor Fitzgerald initiated coverage on shares of Dynavax Technologies in a research report on Friday, September 15th. They issued an “overweight” rating and a $24.00 target price for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Dynavax Technologies currently has a consensus rating of “Buy” and a consensus target price of $25.17.

Shares of Dynavax Technologies (NASDAQ DVAX) traded up $0.65 during mid-day trading on Wednesday, reaching $18.30. 902,439 shares of the company’s stock were exchanged, compared to its average volume of 2,038,894. Dynavax Technologies has a 52-week low of $3.70 and a 52-week high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.15. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.28 million. During the same quarter in the previous year, the business posted ($0.90) EPS. The firm’s revenue was down 68.8% compared to the same quarter last year. equities analysts expect that Dynavax Technologies will post -1.72 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its position in shares of Dynavax Technologies by 2.3% during the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 456 shares during the last quarter. Nationwide Fund Advisors grew its position in shares of Dynavax Technologies by 2.5% during the 2nd quarter. Nationwide Fund Advisors now owns 28,359 shares of the biopharmaceutical company’s stock valued at $274,000 after buying an additional 692 shares during the last quarter. Parametric Portfolio Associates LLC grew its position in shares of Dynavax Technologies by 3.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 939 shares during the last quarter. Patriot Financial Group Insurance Agency LLC grew its position in shares of Dynavax Technologies by 16.5% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 1,700 shares during the last quarter. Finally, Legal & General Group Plc grew its position in shares of Dynavax Technologies by 18.5% during the 2nd quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 1,950 shares during the last quarter. 70.61% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “BidaskClub Downgrades Dynavax Technologies (DVAX) to Hold” was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/10/bidaskclub-downgrades-dynavax-technologies-dvax-to-hold.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.